Stay updated on Somapacitan vs Placebo & Norditropin in GH Deficiency Clinical Trial

Sign up to get notified when there's something new on the Somapacitan vs Placebo & Norditropin in GH Deficiency Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Somapacitan vs Placebo & Norditropin in GH Deficiency Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:45:43.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the efficacy comparison between once weekly dosing of NNC0195-0092 (somapacitan) and other treatments in adults with growth hormone deficiency in a clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:19.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for study participants, specifying age range, prior treatments, and specific health conditions required for inclusion. Previously, no information was provided under the Participation Criteria Collaborators section.
    Difference
    21%
    Check dated 2024-05-22T21:10:05.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T21:55:51.000Z thumbnail image

Stay in the know with updates to Somapacitan vs Placebo & Norditropin in GH Deficiency Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Somapacitan vs Placebo & Norditropin in GH Deficiency Clinical Trial page.